Skip to main content
. 2008 Aug 27;105(35):13051–13056. doi: 10.1073/pnas.0804280105

Fig. 1.

Fig. 1.

Telomere length in lymphocytes from IIP patients and families with known telomerase mutations compared with healthy controls. (A) IIP patients, in yellow, have shorter telomeres than age-matched controls (P < 0.0001, Wilcoxon signed rank). IIP patients [60 of 62 (97%)] have telomeres shorter than the median of healthy controls (P < 0.0001). Of 62 IIP patients, 50 (81%) carried the diagnosis of IPF. (B) Detailed view of A with individuals with features of a telomere syndrome highlighted in red: *, a 77-year-old IPF patient with hTR 325G→T mutation; §, a patient with very short telomeres who had chronic unexplained thrombocytopenia, a feature of subclinical aplastic anemia; ‡, two individuals with both IPF and cryptogenic liver cirrhosis who have short telomeres. Ten percent of IIP patients (6 of 62) have short telomeres below the first percentile; a range predictive of the presence of a telomerase mutation. (C) Telomere length from 45 individuals from 10 families with known mutations in hTERT (n = 17), hTR (n = 3), and DKC1 (n = 4). (D) Bar graph illustrates the mean difference in telomere length from the median of age-matched healthy controls. Compared with noncarriers whose telomere length was similar to controls (P = 0.304, Wilcoxon signed rank), both sporadic IIP patients and known telomerase mutation carriers had shorter telomeres (P < 0.0001 for both).